In order to target both upstream ER and downstream CDK4/6 signaling for cancer control, the combination of CDK inhibitors with endocrine therapy has been used successfully in metastatic ER+ breast cancer, and to a moderate extent in earlier-stage, non-metastatic breast cancer7–12. This evidence concerns the gene ESR1 and breast carcinoma.